// App-Quantinova.ai

4508 : First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.

Researchers

Presenter

  • Peter H. O'Donnell

Principal Investigators

  • Arjun Vasant Balar

  • Jacqueline Vuky

  • Daniel Castellano

  • Joaquim Bellmunt

  • Thomas Powles

  • Dean F. Bajorin

  • Petros Grivas

  • Noah M. Hahn

  • Elizabeth R. Plimack

  • Jin Zhi Xu

  • James Luke Godwin

  • Blanca Homet Moreno

  • Ronald De Wit

Medical Centers

  • The University of Chicago Medical Center, Chicago, IL

  • Perlmutter Cancer Center, NYU Langone Health, New York, NY, Oregon Health and Science University, Portland, OR, Hospital Universitario 12 de Octubre, Madrid, Spain

  • Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Memorial Sloan Kettering Cancer Center, New York, NY, University of Washington, Seattle, WA, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, MD, Fox Chase Cancer Center, Philadelphia, PA, Merck & Co., Inc., Kenilworth, NJ, Erasmus MC Cancer Institute, Rotterdam, Netherlands

Locations

  • Spain

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Peripheral Nervous System

  • Cardiovascular (CVS)

Disease

  • Advanced Urothelial Carcinoma

  • Peripheral neuropathy

  • Bladder Cancer

  • Congestive heart failure

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • NCT02335424

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved